GGrantIndex
← Leaderboards

David Kabat

Oregon Health And Science University

Google Scholar ↗PubMed ↗ORCID ↗
$9,683,022
Attributed
$9,683,022
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY2005–14
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$9,683,022 · 7

By mechanism

R01$9,433,074 · 5
R56$197,400 · 1
R21$52,548 · 1

Top collaborators

No co-investigators on record.

Most similar at Oregon Health And Science University

Same institution · by research overlap

Others in their field

Top investigators on “Hiv Envelope Protein Gp120”

Research focus

Hiv Envelope Protein Gp120Protein Structure FunctionBinding (Molecular Function)Hiv-1CellsXenopus OocyteLaboratory RabbitViralMolecular CloningCell LineAidsHuman Immunodeficiency Virus 1Virus ProteinHost Organism InteractionInvestigationT-LymphocyteInhibitor/AntagonistResourcesVariantMutationAcquired Immunodeficiency SyndromeReceptor BindingVirus ReplicationInsight

Grant awards (34)

Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$318,402
R01 · FY2014 · CA · contact PI
Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$308,554
R01 · FY2013 · CA · contact PI
Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$328,249
R01 · FY2012 · CA · contact PI
Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$328,249
R01 · FY2011 · CA · contact PI
Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$338,401
R01 · FY2010 · CA · contact PI
Control of HIV-1 Entry Rates by Antibodies and CCR5 Regions$197,400
R56 · FY2009 · CA · contact PI
Drug development for Vif-APOBEC3G in HIV-1/AIDS$363,258
R01 · FY2008 · AI · contact PI
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS$330,059
R01 · FY2008 · AI · contact PI
ENTRY MECHANISMS IN HIV-1/AIDS$322,145
R01 · FY2008 · CA · contact PI
Drug development for Vif-APOBEC3G in HIV-1/AIDS$360,092
R01 · FY2007 · AI · contact PI
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS$324,492
R01 · FY2007 · AI · contact PI
ENTRY MECHANISMS IN HIV-1/AIDS$322,145
R01 · FY2007 · CA · contact PI
Drug development for Vif-APOBEC3G in HIV-1/AIDS$369,062
R01 · FY2006 · AI · contact PI
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS$336,918
R01 · FY2006 · AI · contact PI
ENTRY MECHANISMS IN HIV-1/AIDS$331,767
R01 · FY2006 · CA · contact PI
ENTRY MECHANISMS IN HIV-1/AIDS$339,750
R01 · FY2005 · CA
Role of Vif in HIV-1 Replication/AIDS$264,250
R01 · FY2005 · AI
ENTRY MECHANISMS IN HIV-1/AIDS$332,406
R01 · FY2004 · CA
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES$269,541
R01 · FY2004 · CA
Role of Vif in HIV-1 Replication/AIDS$263,740
R01 · FY2004 · AI
CD4 AND CORECEPTORS IN HIV-1/AIDS$284,402
R01 · FY2003 · CA
Role of Vif in HIV-1 Replication/AIDS$263,230
R01 · FY2003 · AI
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES$261,742
R01 · FY2003 · CA
CD4 AND CORECEPTORS IN HIV-1/AIDS$276,118
R01 · FY2002 · CA
Role of Vif in HIV-1 Replication/AIDS$263,230
R01 · FY2002 · AI
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES$254,171
R01 · FY2002 · CA
CD4 AND CORECEPTORS IN HIV-1/AIDS$268,076
R01 · FY2001 · CA
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES$246,822
R01 · FY2001 · CA
Role of Vif in HIV-1 Replication/AIDS$229,563
R01 · FY2001 · AI
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS$209,899
R01 · FY2001 · CA
Role of Vif in HIV-1 Replication/AIDS$52,548
R21 · FY2001 · AI
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES$260,293
R01 · FY2000 · CA
CD4 AND CORECEPTORS IN HIV-1/AIDS$260,264
R01 · FY2000 · CA
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS$203,784
R01 · FY2000 · CA